Berupipam (hemifumarate)

Berupipam hemifumarate is a selective antagonist of the dopamine D1 receptor (dopamine D1 receptor) . Berupipam hemifumarate is a substrate of UDP-glucuronosyltransferase (UGT) and has a high affinity for UGT enzymes but a relatively low conversion rate. The glucuronidation rate of Berupipam hemifumarate varies among different species and genders. Berupipam hemifumarate can be used for the study of psychotic disorders[1].

Product Specifications

CAS Number

[172940-14-6]

UNSPSC

12352005

Target

Dopamine Receptor; UGT

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

CN1C[C@H](C2=C3C(CCO3)=CC(Br)=C2)C4=CC(O)=C(Cl)C=C4CC1.OC(/C=C/C(O)=O)=O.[1/2]

Molecular Formula

C23H23BrClNO6

Molecular Weight

524.79

References & Citations

[1]Hansen KT, Stentoft K. Characterization of benzazepine UDP-glucuronosyl-transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25 (6) :611-22.